A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

This study has been terminated.
(Low accrual)
Sponsor:
Collaborators:
Bayer
Celgene Corporation
Information provided by (Responsible Party):
Veeda Oncology
ClinicalTrials.gov Identifier:
NCT00607438
First received: January 22, 2008
Last updated: May 9, 2012
Last verified: May 2012
  Purpose

This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.

Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuously.

Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.


Condition Intervention Phase
Breast Cancer
Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)
Drug: Sorafenib (Nexavar)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Veeda Oncology:

Primary Outcome Measures:
  • To evaluate the progression-free survival (PFS)and duration of response of the combination of weekly Abraxane and continuous Nexavar as first-line treatment for patients with locally advanced or metastatic breast cancer. [ Time Frame: Survival every 3 months for two years starting from the end of study date. Duration of response every 8 weeks while on treatment. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the response rate. [ Time Frame: Every 8 weeks while on study treatment. ] [ Designated as safety issue: No ]
  • Evaluate the 1 and 2 year survival rate. [ Time Frame: Every 3 months for 2 years starting from the end of therapy visit date ] [ Designated as safety issue: No ]
  • Evaluate the toxicities of the combination of Abraxane and Nexavar [ Time Frame: At each clinic visit or if reported by subject. ] [ Designated as safety issue: Yes ]

Enrollment: 16
Study Start Date: September 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)
    125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
    Other Name: Abraxane
    Drug: Sorafenib (Nexavar)
    400 mg orally twice a day continuously (even during rest week) starting on Day 1.
    Other Name: Nexavar
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have signed an IRB-approved informed consent.
  2. Patients must have histologically confirmed locally advanced or metastatic breast cancer.
  3. Patients must be HER2-negative.
  4. Patients must have measurable disease, as defined by the RECIST criteria.
  5. Patients may have received prior adjuvant chemotherapy for breast cancer, including taxane-containing regimens, provided this treatment was completed at least 12 months prior to enrollment.
  6. Patients must be <18 years of age.
  7. Patients must have an ECOG Performance Status of 0 or 1.
  8. Patients' estimated life expectancy must be at least 12 weeks.
  9. Patients must have adequate liver functions defined as: total bilirubin within normal limits and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 X upper limit of normal (ULN) (or < 5 X ULN for patients with liver involvement).
  10. Patients must have alkaline phosphatase ≤ 2.5 X ULN. Alkaline phosphatase may be > 2.5 x ULN if bone metastasis is present in the absence of liver metastasis, and the patient's bilirubin ≤ ULN.
  11. Patients must have adequate renal function defined as: creatinine ≤ 1.5 mg/dL.
  12. Patients must have adequate bone marrow function, including absolute neutrophil count (ANC) >1500/µL, platelet count >100,000/µL, and hemoglobin >9 g/dL.
  13. Patients must have a normal baseline left ventricular ejection fraction (LVEF).
  14. Patients must be normotensive. Patients taking anti-hypertensive medication must have blood pressure controlled and not greater than 140/90.
  15. International Normalized Ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits.
  16. Patients must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal for at least 12 months.
  17. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter.
  18. Patients must be willing and able to comply with scheduled visits, treatment plan and laboratory testing, and be accessible for follow-up.

Exclusion Criteria:

  1. Patients who have received prior chemotherapy for the treatment of locally advanced or metastatic breast cancer.
  2. Patients who have received prior Abraxane or Nexavar.
  3. Patients who have a history of hypersensitivity or a suspected allergy to taxanes, any of the components in taxanes, Abraxane, or Nexavar.
  4. Patients with serious intercurrent medical or psychiatric illness, including serious active infection.
  5. Patients with untreated or active brain metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.
  6. Patients with a history of thrombosis.
  7. Patients with thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
  8. Patients with symptomatic congestive heart failure or a baseline echocardiogram with LVEF < ULN.
  9. Patients with congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina (anginal symptoms at rest), or new onset angina (began within the last 3 months), or myocardial infarction within the past 6 months.
  10. Patients with cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
  11. Patients with a history of, or active, bowel perforation or inflammatory bowel disease.
  12. Patients with active peptic ulcer disease or symptoms to suggest possible ulcer (discontinuation of chronic NSAID therapy advised, or if not possible, use of proton-pump inhibitors recommended.)
  13. Patients planning to receive any concurrent therapy to treat locally advanced or metastatic breast cancer during the study treatment period.
  14. Any patient who is pregnant or lactating.
  15. Patients with proteinuria > +1 by baseline dipstick, or if +2, 24-hour urine total protein > 250 mg.
  16. Patients who have undergone major surgery, open biopsy, or significant traumatic injury within 28 days, or minor surgery within 14 days. (The placement of a Mediport or other vascular access device is permitted if performed at least 7 days prior to registration).
  17. Patients with > Grade 2 peripheral neuropathy (NCI-CTC v3.0) or any painful neuropathy.
  18. Patients who have experienced any type of bone fracture within 12 months or who have undergone joint replacement surgery within 6 months.
  19. Patients with a serious non-healing wound.
  20. Patients with known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
  21. Patients requiring anticoagulants (with the exception of low-dose Coumadin, ASA, Plavix or Heparin for maintenance of vascular access patency).
  22. Patients with evidence or history of bleeding diathesis or coagulopathy.
  23. Patients experiencing any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.
  24. Patients with pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.
  25. Patients with any condition that impairs a patient's ability to swallow whole pills or patients with any malabsorption problems.
  26. Patients who use St. John's Wort or rifampin (rifampicin).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00607438

Locations
United States, Ohio
Veeda Oncology
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Veeda Oncology
Bayer
Celgene Corporation
Investigators
Principal Investigator: Barry Mirtsching, MD Veeda Oncology
  More Information

No publications provided

Responsible Party: Veeda Oncology
ClinicalTrials.gov Identifier: NCT00607438     History of Changes
Other Study ID Numbers: I-06-025
Study First Received: January 22, 2008
Last Updated: May 9, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Veeda Oncology:
Locally Advanced or Metastatic

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Sorafenib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 28, 2014